Tosi 2003

1 Treatments

Studied treatment  metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d

Control treatment  metformin (500 to 3,000 mg/d),

Concomittant treatments  -

2 Patients

Patients  -

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  double-blind

Design  Cross over

Centers  -

Geographical area  -

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References